Antibody-drug conjugates for advanced/recurrent high-grade endometrial cancer: potential targets, strategies and challenges
Yusuke Matoba, Esther Rodman, Maryam Azimi-Mohammadabadi, Sara Bouberhan et autres
0 citationsResearch Square
Oladapo Yeku
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
5Publications signalées
4Citations signalées
3Affiliations récentes
Institutions déclarées
Domaines associés
HER2/EGFR in Cancer ResearchPARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentImmunotherapy and Immune ResponsesEndometrial and Cervical Cancer Treatments
Publications récentes
First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma
Helen D. Clark, Samira Aghlara-Fotovat, Jake Schladenhauffen, Jonathon DeBonis et autres
1 citationClinical Cancer Research
Trastuzumab pamirtecan (DB-1303/BNT323) in patients with previously treated HER2-expressing advanced/metastatic endometrial cancer: First global clinical phase 2 data
Bhavana Pothuri, Debra Richardson, Vicky Makker, Whitfield Growdon et autres
3 citationsGynecologic Oncology
Rinatabart sesutecan (Rina-S) plus bevacizumab (BEV) for patients (pts) with recurrent ovarian cancer (OC): First disclosure from cohort D2 of the phase 1/2 RAINFOL-01 study
Cara Mathews, Jessica Thomes Pepin, Noelle Cloven, Justin Call et autres
0 citationsGynecologic Oncology
IMA203CD8 PRAME-directed T-cell Receptor (TCR) T-cell therapy in ovarian cancer: results from a phase 1a study
Sarah Taylor, Martin Wermke, Winfried Alsdorf, Amir Jazaeri et autres
0 citationsGynecologic Oncology
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.